Raymond James Financial’s Pulmonx LUNG Stock Holding History

Raymond James Financial’s Portfolio LUNG Stock Details LUNG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-183	Closed	-$474	–	5971
2025 Q2	$474	Buy	+183	New	+$722	﹤0.01%	6676

Other funds holding LUNG

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

KLP

Kent Lake PR Anasco, Puerto Rico $198M AUM 5.21% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Raymond James Financial's LUNG Position: Q3 2025 in Review

Raymond James Financial sold out of Pulmonx (LUNG) in Q3 2025, closing a stake of 183 shares — an estimated $474 sold.

Raymond James Financial first reported a position in LUNG in Q2 2025 and held it in 1 quarter. The position peaked at $474 in Q2 2025. 107 funds tracked by Wall St. Rank hold LUNG as of Q3 2025.

Raymond James Financial reported no remaining Pulmonx position as of Q3 2025 after selling out during the quarter.
Raymond James Financial sold 183 Pulmonx shares in Q3 2025, an estimated $474.
Raymond James Financial first reported a position in Pulmonx in Q2 2025 and held it in 1 quarter.
Raymond James Financial's Pulmonx position peaked at $474 in Q2 2025.
107 funds tracked by Wall St. Rank held Pulmonx as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.